With strong determination, 
Nihon Kohden will pursue our transformation
into a global MedTech company
toward the final year of the Three-year Business Plan,
BEACON 2030 Phase II.
 

Hirokazu Ogino,  
Representative Director,
President and Chief Executive Officer

First, we would like to express our sincere gratitude for our shareholders’ continued support.

We hereby report the results for FY2025 ended March 31, 2026.

In FY2025, overall sales increased and operating income decreased. In Japan, sales of third-party products decreased, while sales of our in-house products increased. Overseas sales achieved double-digit growth, as sales in all regions increased favorably. Operating income decreased, as domestic sales decreased and SG&A expenses increased. Overseas sales ratio, consumables and services sales ratio, and in-house sales ratio were above the Company’s target, mainly due to the impact of the consolidation of Ad-Tech in the U.S. Improving profitability through top-line growth remained an issue, as SG&A ratio increased due to sales falling short of forecasts.
The Company decided to pay a year-end dividend of 16 yen per share. As a result, the full-year dividend for FY2025 increased by 1 yen to 32 yen per share, including the interim dividend of 16 yen per share. As the Company also acquired 5 billion yen of its own shares, the consolidated total return ratio was 70% in FY2025. The full-year dividend for FY2026 will be increased 1 yen to 33 yen per share. The Company also cancelled 3 million shares of its treasury shares in June 2026. 
In FY2026, which is the final year of the Three-year Business Plan, Nihon Kohden will implement its six key measures. The Company will focus on selling in-house products, consumables, and services. However, overall sales are expected to decline due to the discontinuation of Abbott products. The Company will improve its profitability by focusing on the growth of its North America Business and the reform of the profit structure. In response to rapid changes in the business environment that were not anticipated at the time of planning, we will pursue further business growth and improve our profit structure. We will also strengthen our organizational structure and capabilities in preparation for the final year of Phase II and the next Medium-term Business Plan.

We deeply appreciate your continued support.